TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03985280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency
Description: Under guidance of combined X-ray and ultrasound the nerves will be located . After local anesthetic aplication cooled RF needle will be apply in the objective position. Cooled RF will be performed for 2:30 minutes at 60 º C degrees.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraaticular steroids and local anesthetic injections
Description: Intraaticular steroids and local anesthetic injections
Study: NCT03389308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diacerein 1% ointment
Description: Topically apply study medication to lesions identified by the Investigator that require.~treatment
Study: NCT01317485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidectomy with primary anastomosis
Description: \[OPEN\] Sigmoidectomy is done according to the guidelines of the American Society of Colon and Rectal Surgeons. The distal transsection margin has to be on the proximal rectum, the proximal margin is determined by the absence of wall thickening due to diverticulitis. The type of anastomosis is done according to the preference of the operating surgeon. A loop ileostomy can be fashioned in order to ensure faecal deviation to the discretion of the surgeon.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidectomy with end-colostomy
Description: \[OPEN\] This is a two-stage procedure with the intention to close the colostomy in a second stage. During the primary surgery, only the perforated diseased part must be resected. There is no need of having the distal transsection line on the proximal rectum.
Study: NCT03990285

Intervention type: DRUG
Group type: OTHER
Intervention: Axumin, Intravenous Solution
Description: To compare 18F-fluciclovine PET uptake measures in glioblastoma patients with tumor progression versus pseudoprogression
Study: NCT01792934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX regimen according to standard procedures

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX regimen according to standard procedures
Study: NCT00847756

Intervention type: PROCEDURE
Intervention: nasopharyngeal swab
Description: A nasopharyngeal swab is taken at the end of the surgical procedure and after 2-3 months.

Intervention type: PROCEDURE
Intervention: nasopharyngeal swab
Description: A nasopharyngeal swab is taken at the end of the surgical procedure and after 2-3 months.
Study: NCT03934710

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug will be administered in solution form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serotonin agonist - 13ug
Description: 13ug lysergic acid diethylamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serotonin agonist - 26ug
Description: 26ug lysergic acid diethylamide
Study: NCT03794713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient support tool
Description: The patient support tool, a software app installed on the smart phones plus a wrist connected to the smart phones by Bluetooth. The wrist could monitor the pulse, which was recorded to the app in the smart phone. Meanwhile, the app could inform to patients about the importance of medication, remind on the medicine intake, share the patients' data with themselves, and warn the patients if the wrist don't wear.
Study: NCT01709981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later
Study: NCT01195363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine SR
Description: quetiapine SR, dose range 200-600mg, each night QHS for 6mos

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: quetiapine sr placebo
Description: quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos
Study: NCT01317485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidectomy with end-colostomy
Description: \[OPEN\] This is a two-stage procedure with the intention to close the colostomy in a second stage. During the primary surgery, only the perforated diseased part must be resected. There is no need of having the distal transsection line on the proximal rectum.
Study: NCT03017846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: Application of topical cantharidin
Study: NCT04584853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib used in combination with standard Endocrine Therapy for 2 years from randomisation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)
Description: Standard of care endocrine therapy for a minimum of 5 years from randomisation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)
Description: Standard of care endocrine therapy for a minimum of 5 years from randomisation
Study: NCT01261546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: * Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~* Ranitidine 5 mg/kg IV, q.d. for 2 days~* Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~* Ranitidine 5 mg/kg IV, q.d. for 2 days.~* Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.
Study: NCT01737658

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Program
Description: Exercise Program for Obese Adolescents

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Program
Description: Exercise Program for Obese Adolescents
Study: NCT03700970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 20mL of Exparel® 1.3% mixed with 20mL of 0.25% bupivacaine, for a total of 40mL of local anesthestic mixture, 20mL to be injected on each side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular bupivacaine
Description: 20mL of 0.25% bupivacaine injected on each side.
Study: NCT01578785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate
Description: Glatiramer acetate 20mg in 0.5ml for subcutaneous injection in a pre-filled syringe (PFS) is administered daily. Each PFS also contains 20mg mannitol dissolved in water for injection.
Study: NCT01792934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen according to standard procedures
Study: NCT01796158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cASBI
Description: In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit.
Study: NCT02240342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow transplant into ovarian artery
Description: Bone marrow progenitors mobilized to peripheral blood, obtained by plasmapheresis and infused into the ovarian artery
Study: NCT04171271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activating kinesthetic motor imagery training
Description: Participants in the activating kinesthetic motor imagery training group will imagine high effort exercises (e.g. planking, boxing, jumping, squats, push-ups) in the sessions in home using the study audio-video motor imagery script for 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxing kinesthetic motor imagery training
Description: Participants in the relaxing kinesthetic motor imagery training group will imagine relaxing (low effort) exercises (e.g. breathing exercises, stretching, body awareness exercises) in home using the study audio-video motor imagery script 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
Study: NCT04840966

Intervention type: DIAGNOSTIC_TEST
Intervention: Flavor test
Description: A simplified self-administrable flavor test has been proposted to all the enrolled subjects

Intervention type: DIAGNOSTIC_TEST
Intervention: Flavor test
Description: A simplified self-administrable flavor test has been proposted to all the enrolled subjects

Intervention type: DIAGNOSTIC_TEST
Intervention: Flavor test
Description: A simplified self-administrable flavor test has been proposted to all the enrolled subjects

Intervention type: OTHER
Intervention: Self-assesment questionnaire
Description: Questionnaire to score subjective chemosensory function (smell and flavor) before and after COVID-19 using a 0-10 scale with 0 corresponding to no smell/flavor perception and 10 corresponding to excellent smell/flavor perception.

Intervention type: OTHER
Intervention: Self-assesment questionnaire
Description: Questionnaire to score subjective chemosensory function (smell and flavor) before and after COVID-19 using a 0-10 scale with 0 corresponding to no smell/flavor perception and 10 corresponding to excellent smell/flavor perception.
Study: NCT02579161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cephalosporins
Description: Patients were randomly assigned to the interventional arm or the control arm through stratified randomization. In addition to perioperative antibiotics, those in the interventional arm only received antibiotic course for up to 24 hours after procedure, while those in the control arm received antibiotics until external catheters were removed based on surgeon preference. Ancef, a 1st generation cephalosporin, was used as the primary antibiotic, which was started within 60 minutes of the procedure. Dosing was 1 gram IV every 8 hours and was adjusted for renal dosing as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cephalosporins
Description: Patients were randomly assigned to the interventional arm or the control arm through stratified randomization. In addition to perioperative antibiotics, those in the interventional arm only received antibiotic course for up to 24 hours after procedure, while those in the control arm received antibiotics until external catheters were removed based on surgeon preference. Ancef, a 1st generation cephalosporin, was used as the primary antibiotic, which was started within 60 minutes of the procedure. Dosing was 1 gram IV every 8 hours and was adjusted for renal dosing as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroquinolones
Description: If the patient has an allergy to penicillin or cephalosporin, then Ciprofloxacin was used instead and started within 120 minutes of the procedure at 400mg IV and would be continued every 12hrs if patient has a normal creatinine clearance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroquinolones
Description: If the patient has an allergy to penicillin or cephalosporin, then Ciprofloxacin was used instead and started within 120 minutes of the procedure at 400mg IV and would be continued every 12hrs if patient has a normal creatinine clearance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: If allergic to penicillin, cephalosporins, and fluoroquinolones, 900 mg Clindamycin started within 60 minutes prior to initial surgical incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: If allergic to penicillin, cephalosporins, and fluoroquinolones, 900 mg Clindamycin started within 60 minutes prior to initial surgical incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin/Gentamicin
Description: 5 mg/kg as a single dose of Gentamicin within 60 minutes prior to surgical incision; given in combination with 2 grams of ampicillin in cases where allergic to fluoroquinolone and cephalosporin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin/Gentamicin
Description: 5 mg/kg as a single dose of Gentamicin within 60 minutes prior to surgical incision; given in combination with 2 grams of ampicillin in cases where allergic to fluoroquinolone and cephalosporin
Study: NCT02609425

Intervention type: DEVICE
Intervention: Stratafix PGA Suture
Description: Subject leak Stricture rates post procedure
Study: NCT03443635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: The intervention educates subjects through the hands-on cooking and nutrition education classes how to buy, cook, store, and consume healthy foods as an adjunct to healthy activity levels and avoidance of such health risks factors as smoking, excessive alcohol intake, and drug use.
Study: NCT01450644

Intervention type: OTHER
Group type: OTHER
Intervention: The Hospital2Home Service
Description: This intervention is a new multiprofessional, patient case conference that is organised for people nearing the end-of-life. Evidenced based guidelines for the management of the physical, psychological, spiritual and end of life-planning needs for these patients will be used in the H2H case conference. A case conference will be organised in their home (or place of their choice). The patient, informal caregiver, H2H CNS, GP, district nurse, social worker and community palliative care nurse are invited to attend. Current and anticipated care needs are discussed, and an action plan is agreed allocating a responsible health care professional for each item. During the case conference, individualised care plans will be made. This is then communicated with local services, primary and specialist teams resulting in streamlining of transfer of data and codifying responsibility for the patient, hospital and community care professionals.

Intervention type: OTHER
Group type: OTHER
Intervention: The Hospital2Home Service
Description: This intervention is a new multiprofessional, patient case conference that is organised for people nearing the end-of-life. Evidenced based guidelines for the management of the physical, psychological, spiritual and end of life-planning needs for these patients will be used in the H2H case conference. A case conference will be organised in their home (or place of their choice). The patient, informal caregiver, H2H CNS, GP, district nurse, social worker and community palliative care nurse are invited to attend. Current and anticipated care needs are discussed, and an action plan is agreed allocating a responsible health care professional for each item. During the case conference, individualised care plans will be made. This is then communicated with local services, primary and specialist teams resulting in streamlining of transfer of data and codifying responsibility for the patient, hospital and community care professionals.
Study: NCT02136043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBASE system 1.1 (active treatment)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBASE system 1.1 (active treatment)
Study: NCT03593174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ossur Rigid Dressing
Description: Removable Rigid Dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elastic Bandage
Description: Usual modality: Elastic bandage
Study: NCT00852410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% lidocaine with 1:100,000 adrenaline
Description: high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% lidocaine with 1:200,000 adrenaline
Description: 1% lidocaine with 1:200,000 adrenaline
Study: NCT01291108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669
Description: AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669
Description: AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669
Description: AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-210669
Description: AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost
Description: bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost
Description: bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
Study: NCT01792934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen according to standard procedures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation (RFA)
Study: NCT01291108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost
Description: bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost
Description: bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost vehicle
Description: bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.

Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost vehicle
Description: bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.
Study: NCT01792934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy (SBRT)
Study: NCT00700648

Intervention type: DRUG
Intervention: insulin aspart
Description: Intravenous NovoRapid dose \& frequency as decided by treating physician
Study: NCT00641732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: TAK-442 40 mg, tablets, orally, once daily for up to 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: TAK-442 80 mg, tablets, orally, once daily for up to 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: TAK-442 10 mg, tablets, orally, twice daily for up to 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: TAK-442 20 mg, tablets, orally, twice daily for up to 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: TAK-442 40mg, tablets, orally, twice daily for up to 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: TAK-442 80 mg, tablets, orally, twice daily for up to 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 30 mg, syringe, subcutaneous injection, twice daily for up to 10 days.
Study: NCT01738061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidimensional lifestyle intervention
Description: Lecture series to increase awareness of the relationship of lifestyle to chronic diseases Individualized review and discussion to understand own health problems Biweekly group meetings to stimulate motivation and exchange ideas
Study: NCT01792934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: may be added to both regimens according to standard procedures
Study: NCT01578785

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo injection; 20 mg mannitol dissolved in 0.5 mL water for subcutaneous injection in a PFS is administered daily.
Study: NCT01524237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2979165
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2979165
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Tablets administered orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Administered intravenously (IV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Administered intravenously (IV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Administered intravenously (IV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Administered intravenously (IV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Administered intravenously (IV)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Administered intravenously (IV)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Administered intravenously (IV)
Study: NCT00890071

Intervention type: OTHER
Intervention: Fluid administration
Description: 500 ml of synthetic colloid (Voluven®, hydroxyethylstarch 6%; Fresenius, Bad Homburg, Germany) infused over 30 minutes
Study: NCT01959399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: oral tablet
Study: NCT02415764

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral/Attitudinal OnTrack Role-Playing Game
Description: The intervention will involve each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes).~While the intervention does not require direct supervision by the research team, technical support will be available for the duration of the study via telephone, instant messaging and email. All participants receive identical baseline surveys and 2-week follow up surveys.